Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: J SEHARASEYON Examiner #: 78224 Date: 7/3/01
Art Unit: 1647 Phone Number 305-1112 Serial Number: 09/454 223
Mail Box and Bldg/Room Location: 10D16 Results Format Preferred (circle): PAPER DISK E-MAIL
~ Box 10C01

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Multimeric forms of TR TNF Superfamily ligands

Inventors (please provide full names): Richard Kornbluth

Earliest Priority Filing Date: 12/09/99

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Describes tumor necrosis factor superfamily (TNFSF) fusion proteins specifically CD40L (CD154).

POINT OF CONTACT:
BARB O'BRYEN
TECH. INFORMATION SPECIALIST
STIC CM1 12C14 308-4291

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: ~~[illegible]~~	NA Sequence (#) _____	STN 1627
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic X	Dr.Link _____
Date Completed: 7-20-01	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: 25	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: 39	Other _____	Other (specify) _____

PTO-1590 (1-2000)

=> fil capl; d que 117; fil wpids; d que 126; fil biotechno; d que 133; fil medl; d que 153; fil embase; d que 161
FILE 'CAPLUS' ENTERED AT 10:25:36 ON 20 JUL 2001

FILE COVERS 1947 - 20 Jul 2001 VOL 135 ISS 5
FILE LAST UPDATED: 19 Jul 2001 (20010719/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

L4	81	SEA FILE=CAPLUS ABB=ON	(TNF OR TUMOR NECROSIS FACTOR)(W)(SUPER FAMILY OR SUPER FAMILY)
L5	10257	SEA FILE=CAPLUS ABB=ON	TUMOR NECROSIS FACTORS+NT/CT
L6	33094	SEA FILE=CAPLUS ABB=ON	TUMOR NECROSIS FACTORS+OLD/CT
L7	24912	SEA FILE=CAPLUS ABB=ON	COLLECTIN#
L8	1981	SEA FILE=CAPLUS ABB=ON	SPD OR (SURFACTANT PROTEIN OR SP)(W)D
L9	847	SEA FILE=CAPLUS ABB=ON	"SURFACTANT PROTEINS (PULMONARY)"+OLD/CT
L10	17	SEA FILE=CAPLUS ABB=ON	TNFSF##
L11	3613	SEA FILE=CAPLUS ABB=ON	CD40# OR CD154 OR (CD(W)(40# OR 154))
L12	1027	SEA FILE=CAPLUS ABB=ON	LTA
L14	247	SEA FILE=CAPLUS ABB=ON	LTB
L15	120289	SEA FILE=CAPLUS ABB=ON	FUSION/OBI
L16	61469	SEA FILE=CAPLUS ABB=ON	MULTIMER? OR TRIMER? OR CHIMER? OR CHIMAER?
L17	7	SEA FILE=CAPLUS ABB=ON	((L4 OR L5 OR L6) OR (L10 OR L11 OR L12) OR L14) AND ((L7 OR L8 OR L9)) AND (L15 OR L16)

FILE 'WPIDS' ENTERED AT 10:25:37 ON 20 JUL 2001

FILE LAST UPDATED: 19 JUL 2001 <20010719/UP>
MOST RECENT DERWENT UPDATE 200140 <200140/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> SDI'S MAY BE RUN ON EVERY UPDATE OR MONTHLY AS OF JUNE 2001.
(EVERY UPDATE IS THE DEFAULT). FOR PRICING INFORMATION
SEE HELP COST <<<

>>> D COST AND SET NOTICE DO NOT REFLECT SUBSCRIBER DISCOUNTS -
SEE HELP COST <<<

>>> FOR UP-TO-DATE INFORMATION ABOUT THE DERWENT CHEMISTRY
RESOURCE, PLEASE VISIT
http://www.derwent.com/chemistryresource/index.html <<<

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES,
SEE http://www.derwent.com/covcodes.html <<<

L19 2 SEA FILE=WPIDS ABB=ON TNFSF##
L20 2875 SEA FILE=WPIDS ABB=ON (TUMOR OR TUMOUR)(W)NECROSIS(W)FACTOR#
OR TNF
L21 100 SEA FILE=WPIDS ABB=ON LTA OR LTB OR (LYMPHOTOXIN# OR LYMPHO
TOXIN#)(W)(ALPHA OR BETA)
L22 237 SEA FILE=WPIDS ABB=ON CD40# OR CD154 OR CD(W)(40# OR 154)
L23 60964 SEA FILE=WPIDS ABB=ON COLLECTIN# OR SPD
L24 58 SEA FILE=WPIDS ABB=ON (SP OR SURFACTANT PROTEIN#)(A)(D OR
PULMONARY)
L25 7432 SEA FILE=WPIDS ABB=ON MULTIMER? OR TRIMER? OR CHIMER? OR
CHIMAER?
L26 2 SEA FILE=WPIDS ABB=ON ((L19 OR L20 OR L21 OR L22)) AND (L24
OR L23) AND L25

FILE 'BIOTECHNO' ENTERED AT 10:25:38 ON 20 JUL 2001

FILE LAST UPDATED: 17 JUL 2001 <20010717/UP>
FILE COVERS 1980 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
/CT AND BASIC INDEX <<<

L27 25123 SEA FILE=BIOTECHNO ABB=ON (TUMOR OR TUMOUR)(W)NECROSIS(W)FACTO
R# OR TNF OR TNFSF##
L28 1548 SEA FILE=BIOTECHNO ABB=ON LTA OR LTB OR (LYMPHOTOXIN# OR
LYMPHO TOXIN#)(W)(ALPHA OR BETA)
L29 2037 SEA FILE=BIOTECHNO ABB=ON CD40# OR CD154 OR CD(W)(40# OR 154)
L30 2049 SEA FILE=BIOTECHNO ABB=ON COLLECTIN# OR SPD
L31 280 SEA FILE=BIOTECHNO ABB=ON (SP OR SURFACTANT PROTEIN#)(A)(D OR
PULMONARY)
L32 20801 SEA FILE=BIOTECHNO ABB=ON MULTIMER? OR TRIMER? OR CHIMER? OR
CHIMAER?
L33 0 SEA FILE=BIOTECHNO ABB=ON (L27 OR L28 OR L29) AND (L30 OR
L31) AND L32

FILE 'MEDLINE' ENTERED AT 10:25:40 ON 20 JUL 2001

FILE LAST UPDATED: 16 JUL 2001 (20010716/UP). FILE COVERS 1958 TO DATE.

On April 22, 2001, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE now contains new records from the former NLM HEALTH STAR database. These records have an Entry Date and Update Date of 20010223.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2001 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1958 through 1965. Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

L41	33187	SEA FILE=MEDLINE ABB=ON	TUMOR NECROSIS FACTOR/CT OR TNFSF##
L42	1781	SEA FILE=MEDLINE ABB=ON	LYMPHOTOXIN/CT
L43	1758	SEA FILE=MEDLINE ABB=ON	ANTIGENS, CD40/CT
L44	1233	SEA FILE=MEDLINE ABB=ON	CD40 LIGAND/CT
L46	810	SEA FILE=MEDLINE ABB=ON	SPD OR (SP OR SURFACTANT OR LUNG OR PULMONARY)(1W)(PROTEIN# OR GLYCOPROTEIN#)(W)D
L47	409	SEA FILE=MEDLINE ABB=ON	SURFACTANT PROTEIN#(2A)(PULMONARY OR LUNG)
L48	134585	SEA FILE=MEDLINE ABB=ON	RECOMBINANT PROTEINS+NT/CT
L50	117864	SEA FILE=MEDLINE ABB=ON	FUSION OR MULTIMER? OR TRIMER? OR CHIMER? OR CHIMAER?
L52	3346	SEA FILE=MEDLINE ABB=ON	CD40# OR CD154 OR CD(W)(40# OR 154)
L53	0	SEA FILE=MEDLINE ABB=ON	((L41 OR L42 OR L43 OR L44) OR L52) AND (L46 OR L47) AND (L48 OR L50)

FILE 'EMBASE' ENTERED AT 10:25:40 ON 20 JUL 2001

FILE COVERS 1974 TO 19 Jul 2001 (20010719/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

L54	12263	SEA FILE=EMBASE ABB=ON	TUMOR NECROSIS FACTOR/CT
L55	2071	SEA FILE=EMBASE ABB=ON	LYMPHOTOXIN/CT
L56	675	SEA FILE=EMBASE ABB=ON	SURFACTANT PROTEIN D/CT OR SPD
L57	11405	SEA FILE=EMBASE ABB=ON	COLLECTIN#
L58	9	SEA FILE=EMBASE ABB=ON	TNFSF##
L59	3286	SEA FILE=EMBASE ABB=ON	CD40# OR CD154 OR CD(W)(40# OR 154)
L60	81673	SEA FILE=EMBASE ABB=ON	FUSION OR MULTIMER? OR TRIMER? OR CHIMER? OR CHIMAER?
L61	0	SEA FILE=EMBASE ABB=ON	(L54 OR L55 OR L58 OR L59) AND L60 AND (L56 OR L57)

```
=> fil CABA, JICST-EPLUS, BIOSIS, CONFSCI, BIOTECHDS
FILE 'CABA' ENTERED AT 10:26:21 ON 20 JUL 2001
COPYRIGHT (C) 2001 CAB INTERNATIONAL (CABI)

FILE 'JICST-EPLUS' ENTERED AT 10:26:21 ON 20 JUL 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'BIOSIS' ENTERED AT 10:26:21 ON 20 JUL 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CONFSCI' ENTERED AT 10:26:21 ON 20 JUL 2001
COPYRIGHT (C) 2001 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 10:26:21 ON 20 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

=> d que 140
L34        79420 SEA (TUMOR OR TUMOUR)(W) NECROSIS(W) FACTOR# OR TNF OR TNFSF##
L35         3121 SEA LTA OR LTB OR (LYMPHOTOXIN# OR LYMPHO TOXIN#)(W)(ALPHA OR
                 BETA)
L36         4810 SEA CD40# OR CD154 OR CD(W)(40# OR 154)
L37        35467 SEA COLLECTIN# OR SPD
L38         1540 SEA (SP OR SURFACTANT PROTEIN#)(A)(D OR PULMONARY)
L39        57386 SEA MULTIMER? OR TRIMER? OR CHIMER? OR CHIMAER?
L40            1 SEA (L34 OR L35 OR L36) AND (L37 OR L38) AND L39

=> dup rem l17,l40,l26
FILE 'CAPLUS' ENTERED AT 10:26:33 ON 20 JUL 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:26:33 ON 20 JUL 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'WPIDS' ENTERED AT 10:26:33 ON 20 JUL 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD
PROCESSING COMPLETED FOR L17
PROCESSING COMPLETED FOR L40
PROCESSING COMPLETED FOR L26
L63            9 DUP REM L17 L40 L26 (1 DUPLICATE REMOVED)
                 ANSWERS '1-7' FROM FILE CAPLUS
                 ANSWER '8' FROM FILE BIOSIS
                 ANSWER '9' FROM FILE WPIDS

=> d ibib ab 1-9; fil hom

L63 ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2001 ACS          DUPLICATE 1
ACCESSION NUMBER:         2001:435124  CAPLUS
DOCUMENT NUMBER:          135:45182
TITLE:                    Multimeric forms of TNF
                          superfamily ligands
INVENTOR(S):              Kornbluth, Richard S.
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 73 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042298	A1	20010614	WO 2000-US7380	20000320

W: AU, CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1999-454223 A 19991209

AB A method for constructing stable bioactive fusion proteins of the difficult to express **tumor necrosis factor superfamily** (**TNFSF**), and particularly members **CD40L** (**CD154**) and RANKL/TRANCE, with **collectins**, particularly pulmonary **surfactant protein D** (**SPD**) is described. Single **trimers** of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The **multimeric** nature of these sol. fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For **CD40L-SPD**, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be esp. useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addn., these and other **TNFSF-collecting** fusion proteins present new possibilities for the expression of highly active, **multimeric**, sol. **TNFSF** members.

REFERENCE COUNT: 2
REFERENCE(S): (1) Gires, O; EMBO J 1999, V16(20), P6131
(2) Pison, U; Eur J Clin Inv 1994, V24(9), P586 CAPLUS

L63 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2001:168035 CAPLUS
DOCUMENT NUMBER: 134:236228
TITLE: **CD40** ligand and **CD40** agonist compositions and methods of use
INVENTOR(S): Ahuja, Seema S.; Bonewald, Lynda F.
PATENT ASSIGNEE(S): Board of Regents, the University of Texas System, USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016180	A2	20010308	WO 2000-US23276	20000824

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-151250 P 19990827
AB Disclosed are uses of compns. contg. one or more **CD40** agonists,

such as **CD40** ligands and/or agonistic anti-**CD40** antibodies, to reduce or prevent cell death, or apoptosis, in bone cells. Methods of treating or preventing bone loss, including osteoporosis, as well as methods of reducing or eliminating the bone loss assocd. with steroid administration are also provided. Further provided are a variety of therapeutic kits and cocktails.

L63 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:392367 CAPLUS
DOCUMENT NUMBER: 133:133979
TITLE: Human SP-A protein variants derived from one or both genes stimulate TNF-.alpha. production in the THP-1 cell line
AUTHOR(S): Wang, Guirong; Phelps, David S.; Umstead, Todd M.; Floros, Joanna
CORPORATE SOURCE: Departments of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA
SOURCE: Am. J. Physiol. (2000), 278(5, Pt. 1), L946-L954
CODEN: AJPHAP; ISSN: 0002-9513
PUBLISHER: American Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In humans, 2 functional genes of surfactant protein (SP) A, SP-A1 and SP-A2, and several alleles of each functional gene have been characterized. SP-A is a **multimeric** mol. consisting of 6 **trimers**. Each **trimer** contains 2 SP-A1 mols. and 1 SP-A2 mol. Until now, it has been unclear whether a single SP-A gene product is functional or whether there are functional differences either among alleles or between single-gene SP-A products and SP-A products derived from both genes. The authors tested the ability of in vitro expressed SP-A variants to stimulate tumor necrosis factor (TNF)-.alpha. prodn. by THP-1 cells. They obsd. that (1) single-gene products and products derived from both genes stimulate TNF-.alpha. prodn., (2) there are differences among SP-A1 and SP-A2 alleles in their ability to stimulate TNF-.alpha. prodn., and (3) the increases in TNF-.alpha. prodn. are lower after treatment with the SP-A1 alleles than after treatment with the SP-A2 alleles. Furthermore, coexpressed SP-As from SP-A1 and SP-A2 genes have a higher activity compared with SP-As from individual alleles or mixed SP-As from SP-A1 and SP-A2 genes. Thus, the SP-A-induced increases in TNF-.alpha. levels differ among SP-A variants and appear to be affected by SP-A genotype and whether SP-A is derived from one or both genes.

REFERENCE COUNT: 43
REFERENCE(S):
(1) Batenburg, J; Prog Lipid Res 1998, V37, P235 CAPLUS
(2) Benne, C; J Infect Dis 1995, V171, P335 CAPLUS
(4) Crouch, E; Am J Respir Cell Mol Biol 1998, V19, P177 CAPLUS
(5) Elhalwagi, B; Biochemistry 1997, V36, P7018 CAPLUS
(6) Floros, J; Am J Respir Cell Mol Biol 1996, V15, P489 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L63 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:795994 CAPLUS
DOCUMENT NUMBER: 132:31744
TITLE: Gene probes used for genetic profiling in healthcare screening and planning
INVENTOR(S): Roberts, Gareth Wyn
PATENT ASSIGNEE(S): Genostic Pharma Ltd., UK
SOURCE: PCT Int. Appl., 745 pp.

Searched by Barb O'Bryen, STIC 308-4291

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964627	A2	19991216	WO 1999-GB1780	19990604

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

GB 1998-12099	A	19980606
GB 1998-13291	A	19980620
GB 1998-13611	A	19980624
GB 1998-13835	A	19980627
GB 1998-14110	A	19980701
GB 1998-14580	A	19980707
GB 1998-15438	A	19980716
GB 1998-15574	A	19980718
GB 1998-15576	A	19980718
GB 1998-16085	A	19980724
GB 1998-16086	A	19980724
GB 1998-16921	A	19980805
GB 1998-17097	A	19980807
GB 1998-17200	A	19980808
GB 1998-17632	A	19980814
GB 1998-17943	A	19980819

AB There is considerable evidence that significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiol. response. In order to bring about the integration of genomics into medical practice and enable design and building of a technol. platform which will enable the everyday practice of mol. medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiol. states of interest. According to the invention, the no. of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide crit. clin. information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies which comprises of the identification of the core group of genes and their sequence variants required to provide a broad base of clin. prognostic information - "genostics". The "Genostic.RTM." profiling of patients and persons will radically enhance the ability of clinicians, healthcare professionals and other parties to plan and manage healthcare provision and the targeting of appropriate healthcare resources to those deemed most in need. The use of this invention could also lead to a host of new applications for such profiling technologies, such as identification of persons with particular work or environment related risk, selection of applicants for employment, training or specific opportunities or for the enhancing of the planning and organization of health services, education

services and social services.

L63 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:795993 CAPLUS
DOCUMENT NUMBER: 132:31743
TITLE: Gene probes used for genetic profiling in healthcare screening and planning
INVENTOR(S): Roberts, Gareth Wyn
PATENT ASSIGNEE(S): Genostic Pharma Limited, UK
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964626	A2	19991216	WO 1999-GB1779	19990604
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9941586	A1	19991230	AU 1999-41586	19990604
AU 9941587	A1	19991230	AU 1999-41587	19990604
GB 2339200	A1	20000119	GB 1999-12914	19990604
EP 1084273	A1	20010321	EP 1999-925207	19990604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.:

GB 1998-12098	A	19980606
GB 1998-28289	A	19981223
GB 1998-16086	A	19980724
GB 1998-16921	A	19980805
GB 1998-17097	A	19980807
GB 1998-17200	A	19980808
GB 1998-17632	A	19980814
GB 1998-17943	A	19980819
WO 1999-GB1779	W	19990604

AB There is considerable evidence that significant factor underlying the individual variability in response to disease, therapy and prognosis lies in a person's genetic make-up. There have been numerous examples relating that polymorphisms within a given gene can alter the functionality of the protein encoded by that gene thus leading to a variable physiol. response. In order to bring about the integration of genomics into medical practice and enable design and building of a technol. platform which will enable the everyday practice of mol. medicine a way must be invented for the DNA sequence data to be aligned with the identification of genes central to the induction, development, progression and outcome of disease or physiol. states of interest. According to the invention, the no. of genes and their configurations (mutations and polymorphisms) needed to be identified in order to provide crit. clin. information concerning individual prognosis is considerably less than the 100,000 thought to comprise the human genome. The identification of the identity of the core group of genes enables the invention of a design for genetic profiling technologies.

L63 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1994:575846 CAPLUS
DOCUMENT NUMBER: 121:175846
TITLE: 3'-Untranslated region of SP-B mRNA mediates inhibitory effects of TPA and TNF-.alpha. on SP-B expression
AUTHOR(S): Pryhuber, Gloria S.; Church, Susan L.; Kroft, Tim; Panchal, Asha; Whitsett, Jeffrey A.
CORPORATE SOURCE: Med. Cent., Children's Hosp., Cincinnati, OH, 45229-3039, USA
SOURCE: Am. J. Physiol. (1994), 267(1, Pt. 1), L16-L24
CODEN: AJPHAP; ISSN: 0002-9513
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Surfactant protein-B (SP-B) is a small hydrophobic polypeptide that enhances spreading and stability of surfactant phospholipids in the alveolus of the lung. Decreased expression of SP-B is assocd. with respiratory failure in premature infants and in adult patients with acute respiratory distress syndrome (ARDS). Tumor necrosis factor-.alpha. (TNF-.alpha.) and 12-O-tetradecanoylphorbol-13 acetate (TPA) cause ARDS-like lung injury in vivo. Inhibitory effects of TPA and TNF-a on SP-B mRNA expression in vitro were mediated by decreased SP-B mRNA stability rather than by decreased rate of SP-B gene transcription. In the present study, a human pulmonary adenocarcinoma cell line, NCI H441-4, was stably transfected with expression vectors consisting of the thymidine kinase (TK) promotor and human growth hormone (hGH) gene, in which the hGH 3'-untranslated region (3'-UTR) was replaced by the 2.0-kb human SP-B cDNA [pTKGH(SP-B2.0)] or the 837-bp human SP-B 3'-UTR [pTKGH(SP-B.837)]. The mRNAs and cellular growth hormone protein generated from the **chimeric** TKGH(SP-B2.0) and TKGH(SP-B.837) genes were each inhibited by .apprx.50% by TPA and TNF-.alpha.. Dexamethasone decreased the inhibitory effects of TPA and TNF-.alpha.. The inhibition of steady-state hGH-SP-B mRNA by TPA and TNF-a was mediated by a cis-active element located in the 3-UTR region of SP-B mRNA.

L63 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1993:118249 CAPLUS
DOCUMENT NUMBER: 118:118249
TITLE: Enrichment method for variant proteins with altered binding properties
INVENTOR(S): Garrard, Lisa J.; Henner, Dennis J.; Bass, Steven; Greene, Roland; Lowman, Henry B.; Wells, James A.; Matthews, David J.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9209690	A2	19920611	WO 1991-US9133	19911203
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
CA 2095633	AA	19920604	CA 1991-2095633	19911203
EP 564531	A1	19931013	EP 1992-902109	19911203
EP 564531	B1	19980325		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 07503600	T2	19950420	JP 1991-502710	19911203

AT 164395	E	19980415	AT 1992-902109	19911203
ES 2113940	T3	19980516	ES 1992-902109	19911203
US 5750373	A	19980512	US 1993-50058	19930430
US 5688666	A	19971118	US 1994-182530	19940114
US 5780279	A	19980714	US 1995-418928	19950405
US 5846765	A	19981208	US 1995-441871	19950516
US 6040136	A	20000321	US 1997-923854	19970903

PRIORITY APPLN. INFO.:

US 1990-621667	A	19901203
US 1991-683400	A	19910410
US 1991-715300	A	19910614
US 1991-743614	A	19910808
US 1988-264611	B2	19881028
US 1991-682400	B2	19910410
WO 1991-US9133	W	19911203
US 1992-864452	B1	19920419
US 1993-50058	A2	19930430
US 1993-161692	A1	19931203
US 1995-418928	A3	19950405
US 1995-463587	A3	19950605

AB A method for selecting variants of proteins such as growth hormone and antibody fragment with altered binding properties for their resp. receptor mols. is provided. The method comprises fusing a gene encoding a protein of interest to at least a portion of the gene for a phage coat protein, e.g. for the C-terminal domain of the gene III coat protein of M13 under control of a transcription-regulating element. The vector is mutated at .gtoreq.1 position within the 1st gene (e.g. by oligonucleotide-directed mutagenesis), and host cells are transformed with the mutant vector and a helper phage having the coat protein gene. Recombinant phagemid particles are formed contg. at least part of the mutant expression vector and capable of transforming the host; conditions are adjusted so that most phagemid particles do not display >1 copy of the fusion protein on the particle surface. The phagemid particles are screened for binding to the target mol. These steps may be repeated. Phagemids presenting human growth hormone (hGH)-gene III protein fusion proteins prepd. as above were fractionated chromatog. on immobilized hGH-binding protein; a single cycle of binding and elution gave >5000-fold enrichment.

L63 ANSWER 8 OF 9 BIOSIS COPYRIGHT 2001 BIOSIS
ACCESSION NUMBER: 2001:39801 BIOSIS
DOCUMENT NUMBER: PREV200100039801
TITLE: **CD40L (CD154)** fusion protein with **pulmonary surfactant protein D** as a prototype for soluble **multimeric TNF** superfamily ligand molecules.
AUTHOR(S): Kornbluth, R. S. (1); Kee, K. (1); Truong, N. H. (1)
CORPORATE SOURCE: (1) University of California San Diego and VA San Diego Healthcare System, La Jolla, CA USA
SOURCE: FASEB Journal, (April 20, 2000) Vol. 14, No. 6, pp. A1162. print.
Meeting Info.: Joint Annual Meeting of the American Association of Immunologists and the Clinical Immunology Society Seattle, Washington, USA May 12-16, 2000
ISSN: 0892-6638.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L63 ANSWER 9 OF 9 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
ACCESSION NUMBER: 1989-154899 [21] WPIDS
DOC. NO. CPI: C1989-068509
TITLE: Novel DNA, plasmid and polypeptide(s) - useful as

anticarcinogenic agents.
DERWENT CLASS: B04 D16
PATENT ASSIGNEE(S): (SENG-I) SEN G
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 01095784	A	19890413	(198921)*		17
JP 08017716	B2	19960228	(199613)		15

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 01095784	A	JP 1987-252174	19871006
JP 08017716	B2	JP 1987-252174	19871006

FILING DETAILS:

PATENT NO	KIND		PATENT NO
JP 08017716	B2	Based on	JP 01095784

PRIORITY APPLN. INFO: JP 1987-252174 19871006
AB JP 01095784 A UPAB: 19930923
DNA having the following amino acid sequences, plasmids contg. the DNA, polypeptides contg. the amino acid sequences, a method for preparing said polypeptides and anticarcinogenic agents comprising the polypeptides are all new.

Met-Val-Arg-Ser-X-Thr-Arg-Thr-Pro Ser-Arg-Lys-pre -Val-Ala-His-Val -Val- which is amino acid sequences of the fourth exon of **TNF** (where X is Ser or Cys).

In an example, from THP-1 cells, mRNA were extracted by centrifugation and ethanol pptn.. By utilising the mRNA, cDNA libraries were formed by Cubler method and Okayama-Barg method. Screening of desired cDNA was conducted by making the obtd. cDNA libraries grow, converting plasmid DNA of double chains to that of single chain, hybridising the cDNA with DNA probes and detecting positive clones by autoradiography.Genome DNA were prepd. by cultivating THP-1 cells, forming a suspension contg. the cells, and **collecting** the DNA by means of centrifugation, alcohol pptn., density gradient method and dialysing. Genome DNA fragments were collected by nick-translation, hybridisation and condensation of specific DNA, fragments.Genome libraries were formed by preparing **chimera** circular DNA and introducing the **chimera** DNA into E.coli RRI. (7) XhoI/PstI fragments were inserted into pUC540 to form pUC540 (**TNF**)x/p. Also XhoI-PstI fragments were digested and the obtd. HincII-PstI fragment, DheI-HincII fragments were synthesised, combined with either chain of a double DNA and inserted into BamHI-PstI site of pUC540(**TNF**)x/p.
0/0

FILE 'HOME' ENTERED AT 10:26:44 ON 20 JUL 2001